newsfilter
← Latest News
Business Wire·

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

-- Phase 2 Study for RLYB212 Expected to Initiate in 2H 2024 -- -- Company to Provide Update on Phase 2 Discussions with European Medicines Agency for RLYB212 in 1H 2024 -- -- Cash Runway Extended into 3Q 2025